# A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

> **NCT06530719** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jin Ying** · enrollment: 54 (estimated)

## Conditions studied

- Lung Neoplasms
- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** Osimertinib mesylate

## Key facts

- **NCT ID:** NCT06530719
- **Lead sponsor:** Jin Ying
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2026-05
- **Final completion:** 2028-05
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06530719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06530719, "A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06530719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*